Skip to main content

Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type

This is a preview of subscription content, access via your institution.

Fig. 1


  1. Senff NJ, Noordijk EM, Kim YH et al (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112(5):1600–1609

    CAS  Article  Google Scholar 

  2. Di Raimondo C, Abdulla FR, Zain J et al (2019) Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol 187(3):e79–e82

    Article  Google Scholar 

  3. Pang A, Au-Yeung R, Leung RYY et al (2019) Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib. Ann Hematol 98(10):2433–2436

    Article  Google Scholar 

  4. Beylot-Barry M, Mermin D, Maillard A et al (2018) A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol 138(9):1982–1989

    CAS  Article  Google Scholar 

  5. Sehn LH, Hertzberg M, Opat S et al (2022) Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 6(2):533–543

    CAS  Article  Google Scholar 

  6. Maurer MJ, Ghesquières H, Jais JP et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32(10):1066–1073

    Article  Google Scholar 

  7. Xu-Monette ZY, Tu M, Jabbar KJ et al (2015) Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget 6(8):5615–5633

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations



SO: was involved in patients care, writing the manuscript and responsible for the concept of this study. KO: was involved in patient care. MN: was involved in patient care.

Corresponding author

Correspondence to Satoko Oka.

Ethics declarations

Ethics approval and consent to participate

The patient provided their written informed consent to receive each regimen, and treatment was administered according to the principles of the Declaration of Helsinki. This study was approved by the Japanese Red Cross Society Wakayama Medical Center ethics committee.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Oka, S., Ono, K. & Nohgawa, M. Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type. Ann Hematol 101, 2353–2354 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: